VFA
ALNY icon

Values First Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Values First Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
3,246
+20
+0.6% +$6.81K 0.56% 55
2025
Q4 		$1.28M Sell
3,226
-656
-17% -$290K 0.67% 48
2025
Q3 		$1.77M Sell
3,882
-65
-2% -$26.5K 0.95% 40
2025
Q2 		$1.29M Sell
3,947
-4,166
-51% -$1.15M 0.7% 48
2025
Q1 		$2.19M Sell
8,113
-879
-10% -$226K 1.28% 16
2024
Q4 		$2.12M Buy
8,992
+202
+2% +$53.1K 1.16% 17
2024
Q3 		$2.42M Buy
8,790
+1,200
+16% +$312K 1.31% 15
2024
Q2 		$1.84M Sell
7,590
-148
-2% -$23.4K 1.11% 31
2024
Q1 		$1.16M Buy
7,738
+755
+11% +$126K 0.68% 45
2023
Q4 		$1.34M Buy
6,983
+476
+7% +$81.1K 0.81% 41
2023
Q3 		$1.15M Sell
6,507
-50
-0.8% -$9.54K 0.74% 42
2023
Q2 		$1.25M Buy
6,557
+146
+2% +$28.9K 0.75% 42
2023
Q1 		$1.28M Buy
6,411
+109
+2% +$22.9K 0.82% 35
2022
Q4 		$1.5M Buy
6,302
+35
+0.6% +$7.46K 1.05% 30
2022
Q3 		$1.25M Buy
6,267
+201
+3% +$38.3K 0.9% 35
2022
Q2 		$885K Sell
6,066
-430
-7% -$61K 0.63% 52
2022
Q1 		$1.06M Buy
6,496
+347
+6% +$52.9K 0.67% 49
2021
Q4 		$1.04M Sell
6,149
-368
-6% -$68.4K 0.62% 56
2021
Q3 		$1.23M Buy
6,517
+213
+3% +$40K 0.8% 43
2021
Q2 		$1.07M Sell
6,304
-130
-2% -$19K 0.73% 49
2021
Q1 		$908K Buy
6,434
+99
+2% +$14.9K 0.67% 52
2020
Q4 		$823K Sell
6,335
-199
-3% -$26.6K 0.66% 54
2020
Q3 		$951K Buy
6,534
+331
+5% +$47K 0.87% 45
2020
Q2 		$919K Sell
6,203
-146
-2% -$19.7K 0.91% 45
2020
Q1 		$691K Buy
6,349
+367
+6% +$42.4K 0.83% 45
2019
Q4 		$689K Buy
+5,982
New +$596K 0.67% 54

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Values First Advisors's ALNY Position: Q1 2026 in Review

Values First Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 0.62% in Q1 2026, buying an estimated $6.81K and bringing the position to 3,246 shares worth $1.07M. The position accounts for 0.56% of the portfolio, ranked #55.

Values First Advisors first reported a position in ALNY in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.42M in Q3 2024. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Values First Advisors held 3,246 shares of Alnylam Pharmaceuticals worth $1.07M as of Q1 2026.
  • Values First Advisors bought 20 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $6.81K.
  • Alnylam Pharmaceuticals made up 0.56% of Values First Advisors's portfolio in Q1 2026, its #55 holding.
  • Values First Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • Values First Advisors's Alnylam Pharmaceuticals position peaked at $2.42M in Q3 2024.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Values First Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.